BioVersys and partners to present AlpE data at The Union World Conference on Lung Health

November 11, 2026

Basel, Switzerland. November 11, 2026, 7.00am CEST

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that it will present new data on alpibectir together with its development partner GSK. The Union World Conference on Lung Health is taking place from 17 to 20 November 2026 in Rio de Janeiro, Brazil.

Presentations will include the latest Phase 2 data on alpibectir in combination with ethionamide (AlpE), in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.

The Union World Conference on Lung Health brings together researchers, practitioners, advocates, policymakers and communities from around the world to share knowledge, exchange ideas and accelerate progress in lung health.

Alpibectir data presentation schedule at the Union Conference

Date and time (BRT)	Presenter	Presentation	Session
Wednesday, 18 November 12:15–12:20	Dr. Simphiwe RN Simelane	E-poster: “Early bactericidal activity, safety, and pharmacokinetics of alpibectir–ethionamide in pulmonary tuberculosis”	EP16 Emerging therapeutics in TB safety, efficacy and early activity
Thursday, 19 November 09:58–10:06	Dr. Michel Pieren, BioVersys	“Alpibectir potentiates ethionamide and ethionamide-sulfoxide activity in M. tuberculosis clinical isolates from a Phase 2a study”	OA24 Alchemy: Dose determination, safety and adverse effects in preclinical and clinical TB trials
Thursday, 19 November 10:16–10:30	Dr. Simphiwe RN Simelane	“Early bactericidal activity, safety and PK of alpibectir-ethionamide in pulmonary tuberculosis: Results from the ENABLE trial”	SY08 Reimagining TB drug development: Phase 2 results from the UNITE4TB platform
Friday, 20 November 13:11–13:28	Dr. Simon Tiberi	“Early bactericidal activity, safety and PK of alpibectir-ethionamide and updates on further development of alpibectir-containing TB regimens”	SS12 Tackling tuberculosis today and for the future: From pipeline innovation to global collaboration Satellite session: 12:15–13:45; chaired by David Barros-Aguirre

About us	Network	Partners
Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos	Analist.nlLinksISIN Glossary	MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x